IMNM - NASDAQ
Immunome, Inc.
$19.78
-0.15%Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
At a Glance
Live SnapshotImmunome, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Immunome, Inc. Cash Flow Statement
IMNM • NASDAQ
| Immunome, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-212.4M | -293M | -106.8M | -36.9M | -24.7M | -17.8M | -10.4M | -7.8M | |
3M | 2.1M | 728K | 631K | 755K | 755K | 615K | 521K | |
0.0 | 0.0 | 0.0 | -7.3M | -500K | 5.5M | 0.0 | 0.0 | |
25.7M | 15.7M | 6.2M | 5.3M | 3.4M | 621K | 14K | 11K | |
8.1M | 149.4M | 80.3M | 7.3M | 4K | -2K | 3K | 9K | |
-15.2M | 14.9M | 12M | 2.2M | 2.8M | -1.2M | 212K | -102K | |
-190.9M | -110.8M | -7.6M | -28.7M | -18.2M | -12.1M | -9.6M | -7.4M | |
INVESTING ACTIVITIES | ||||||||
-9.7M | -7.2M | -831K | -248K | -79K | -586K | -233K | -228K | |
(0.0) | (0.0) | (9.3M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-123.3M | -186.6M | -38.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
200M | 155M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-6.2M | -46.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(60.8M) | -85.1M | -30.5M | -248K | -79K | -586K | -233K | -228K | |
FINANCING ACTIVITIES | ||||||||
640.4M | 250M | 34K | 32K | 27.2M | 44.9M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -113K | 49K | 6.2M | -551K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -35K | (0.0) | |
0.0 | -9.5M | 116.4M | 0.0 | 656K | -6M | -30K | 0.0 | |
640.4M | 240.5M | 116.4M | 32K | 27.8M | 49.9M | 10.8M | -551K | |
CASH FLOW SUMMARY | ||||||||
510.2M | 44.7M | 78.4M | -28.9M | 9.5M | 37.2M | 941K | -8.2M | |
143.5M | 98.8M | 20.4M | 49.3M | 39.9M | 2.6M | 1.7M | 9.9M | |
653.7M | 143.5M | 98.8M | 20.4M | 49.3M | 39.9M | 2.6M | 1.7M | |
-200.6M | -164.3M | -8.4M | -28.9M | -18.3M | -12.7M | -9.8M | -7.6M |
SEC Filings
IMNM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 09, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 03, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 03, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 17, 2025 | December 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 15, 2025 | December 15, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 06, 2025 | August 06, 2025 | 2025 |
Related Guides
Continue your IMNM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.